Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-0c9e6c673a48a176c2c1114fdf6885b8"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-0c9e6c673a48a176c2c1114fdf6885b8"/>
<resource>
<Composition>
<id value="composition-en-0c9e6c673a48a176c2c1114fdf6885b8"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-0c9e6c673a48a176c2c1114fdf6885b8"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-0c9e6c673a48a176c2c1114fdf6885b8</b></p><a name="composition-en-0c9e6c673a48a176c2c1114fdf6885b8"> </a><a name="hccomposition-en-0c9e6c673a48a176c2c1114fdf6885b8"> </a><a name="composition-en-0c9e6c673a48a176c2c1114fdf6885b8-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/06/376/001-005</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - irbesartan</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/06/376/001-005"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp0c9e6c673a48a176c2c1114fdf6885b8"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - irbesartan"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Irbesartan Zentiva is and what it is used for</li><li>What you need to know before you take Irbesartan Zentiva</li><li>How to take Irbesartan Zentiva</li><li>Possible side effects</li><li>How to store Irbesartan Zentiva</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What irbesartan is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What irbesartan is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Irbesartan Zentiva belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body which binds to receptors in blood vessels causing them to tighten. This results in an increase in blood pressure. Irbesartan Zentiva prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower. Irbesartan Zentiva slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.</p><p>Irbesartan Zentiva is used in adult patients</p><p>to treat high blood pressure (essential hypertension)</p><p>to protect the kidney in patients with high blood pressure, type 2 diabetes and laboratory evidence of impaired kidney function.</p></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take irbesartan"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take irbesartan"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Irbesartan Zentiva</p><p>if you are allergic to irbesartan or any other ingredients of this medicine (listed in section 6)</p><p>if you are more than 3 months pregnant. (It is also better to avoid Irbesartan Zentiva in early pregnancy see pregnancy section)</p><p>if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>Warning and precautions Talk to your doctor before taking Irbesartan Zentiva and if any of the following apply to you:</p><p>if you get excessive vomiting or diarrhoea</p><p>if you suffer from kidney problems</p><p>if you suffer from heart problems</p><p>if you receive Irbesartan Zentiva for diabetic kidney disease. In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function</p><p>if you develop low blood sugar levels (symptoms may include sweating, weakness, hunger, dizziness, trembling, headache, flushing or paleness, numbness, having a fast, pounding heart beat), particularly if you are being treated for diabetes.</p><p>if you are going to have an operation (surgery) or be given anaesthetics</p><p>if you are taking any of the following medicines used to treat high blood pressure: * an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. * aliskiren Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>See also information under the heading Do not take Irbesartan Zentiva .</p><p>You must tell your doctor if you think you are (or might become) pregnant. Irbesartan Zentiva is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>Children and adolescents This medicinal product should not be used in children and adolescents because the safety and efficacy have not yet been fully established.</p><p>Other medicines and Irbesartan Zentiva Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Your doctor may need to change your dose and/or to take other precautions. If you are taking an ACE-inhibitor or aliskiren (see also information under the headings Do not take Irbesartan Zentiva and Warnings and precautions ).</p><p>You may need to have blood checks if you take:</p><p>potassium supplements</p><p>salt substitutes containing potassium</p><p>potassium-sparing medicines (such as certain diuretics)</p><p>medicines containing lithium</p><p>repaglinide (medication used for lowering blood sugar levels)</p><p>If you take certain painkillers, called non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.</p><p>Irbesartan Zentiva with food and drink Irbesartan Zentiva can be taken with or without food.</p><p>Pregnancy and breast-feeding Pregnancy You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Irbesartan Zentiva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Irbesartan Zentiva. Irbesartan Zentiva is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>Breast-feeding Tell your doctor if you are breast-feeding or about to start breast-feeding. Irbesartan Zentiva is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>Driving and using machines Irbesartan Zentiva is unlikely to affect your ability to drive or use machines. However, occasionally dizziness or weariness may occur during treatment of high blood pressure. If you experience these, talk to your doctor before attempting to drive or use machines.</p><p>Irbesartan Zentiva contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Irbesartan Zentiva contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take irbesartan"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take irbesartan"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Method of administration Irbesartan Zentiva is for oral use. Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water). You can take Irbesartan Zentiva with or without food. Try to take your daily dose at about the same time each day. It is important that you continue to take Irbesartan Zentiva until your doctor tells you otherwise.</p><p>Patients with high blood pressure The usual dose is 150 mg once a day (two tablets a day). The dose may later be increased to 300 mg (four tablets a day) once daily depending on blood pressure response.</p><p>Patients with high blood pressure and type 2 diabetes with kidney disease In patients with high blood pressure and type 2 diabetes, 300 mg (four tablets a day) once daily is the preferred maintenance dose for the treatment of associated kidney disease.</p><p>The doctor may advise a lower dose, especially when starting treatment in certain patients such as those on haemodialysis, or those over the age of 75 years.</p><p>The maximal blood pressure lowering effect should be reached 4-6 weeks after beginning treatment.</p><p>Use in children and adolescents Irbesartan Zentiva should not be given to children under 18 years of age. If a child swallows some tablets, contact your doctor immediately.</p><p>If you take more Irbesartan Zentiva than you should If you accidentally take too many tablets, contact your doctor immediately.</p><p>If you forget to take Irbesartan Zentiva If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these effects may be serious and may require medical attention.</p><p>As with similar medicines, rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan. If you get any of these symptoms or get short of breath, stop taking Irbesartan Zentiva and contact your doctor immediately.</p><p>The frequency of the side effects listed below is defined using the following convention: Very common: may affect more than 1 in 10 people</p><p>Common: may affect up to 1 in 10 people Uncommon: may affect up to 1 in 100 people</p><p>Side effects reported in clinical studies for patients treated with Irbesartan Zentiva were:</p><p>Very common (may affect more than 1 in 10 people): if you suffer from high blood pressure and type 2 diabetes with kidney disease, blood tests may show an increased level of potassium.</p><p>Common (may affect up to 1 in 10 people): dizziness, feeling sick/vomiting, fatigue and blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase enzyme). In patients with high blood pressure and type 2 diabetes with kidney disease, dizziness when getting up from a lying or sitting position, low blood pressure when getting up from a lying or sitting position, pain in joints or muscles and decreased levels of a protein in the red blood cells (haemoglobin) were also reported.</p><p>Uncommon (may affect up to 1 in 100 people): heart rate increased, flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (problems with sexual performance), chest pain.</p><p>Some undesirable effects have been reported since marketing of Irbesartan Zentiva. Undesirable effects where the frequency is not known are: feeling of spinning, headache, taste disturbance, ringing in the ears, muscle cramps, pain in joints and muscles, decreased number of red blood cells (anaemia symptoms may include tiredness, headaches, being short of breath when exercising, dizziness and looking pale), reduced number of platelets, abnormal liver function, increased blood potassium levels, impaired kidney function, inflammation of small blood vessels mainly affecting the skin (a condition known as leukocytoclastic vasculitis), severe allergic reactions (anaphylactic shock) and low blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store irbesartan"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store irbesartan"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30 C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Irbesartan Zentiva contains</p><p>The active substance is irbesartan. Each tablet of Irbesartan Zentiva 75 mg contains 75 mg irbesartan.</p><p>The other ingredients are microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica, pregelatinised maize starch, and poloxamer 188. Please see section 2 Irbesartan Zentiva contains lactose .</p><p>What Irbesartan Zentiva looks like and contents of the pack Irbesartan Zentiva 75 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2771 engraved on the other side.</p><p>Irbesartan Zentiva 75 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets. Unidose blister packs of 56 x 1 tablet for delivery in hospitals are also available.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder: Zentiva k.s.<br/>U kabelovny 102 37 Prague Czech Republic</p><p>Manufacturer: Sanofi Winthrop Industrie 1 Rue de la vierge Ambar s et Lagrave 33 565 Carbon Blanc cedex France</p><p>Sanofi Winthrop Industrie 30-36 Avenue Gustave Eiffel 37 100 Tours<br/>France</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.</p><p>Belgi /Belgique/Belgien Zentiva, k.s. T l/Tel: +32 280 86 <a href="mailto:PV-Belgium@zentiva.com">PV-Belgium@zentiva.com</a></p><p>Lietuva Zentiva, k.s. Tel: +370 <a href="mailto:52152PV-Lithuania@zentiva.com">52152PV-Lithuania@zentiva.com</a></p><p>Zentiva, k.s. : <a href="mailto:+35924417PV-Bulgaria@zentiva.com">+35924417PV-Bulgaria@zentiva.com</a></p><p>Luxembourg/Luxemburg Zentiva, k.s. T l/Tel: +352 208 <a href="mailto:82PV-Luxembourg@zentiva.com">82PV-Luxembourg@zentiva.com</a> esk republika Zentiva, k.s. Tel: +420 267 241 <a href="mailto:PV-Czech-Republic@zentiva.com">PV-Czech-Republic@zentiva.com</a> Magyarorsz g Zentiva Pharma Kft. Tel.: +36 1 299 <a href="mailto:1PV-Hungary@zentiva.com">1PV-Hungary@zentiva.com</a> Danmark Zentiva Denmark ApS Tlf: +45 787 68 <a href="mailto:PV-Denmark@zentiva.com">PV-Denmark@zentiva.com</a></p><p>Malta Zentiva, k.s. Tel: +356 277 82 <a href="mailto:PV-Malta@zentiva.com">PV-Malta@zentiva.com</a> Deutschland Zentiva Pharma GmbH<br/>Tel: +49 (0) 800 53 53 <a href="mailto:PV-Germany@zentiva.com">PV-Germany@zentiva.com</a></p><p>Nederland Zentiva, k.s. Tel: +31 202 253 <a href="mailto:PV-Netherlands@zentiva.com">PV-Netherlands@zentiva.com</a></p><p>Eesti Zentiva, k.s. Tel: +372 52 <a href="mailto:70PV-Estonia@zentiva.com">70PV-Estonia@zentiva.com</a></p><p>Norge Zentiva Denmark ApS Tlf: +47 219 66 <a href="mailto:PV-Norway@zentiva.com">PV-Norway@zentiva.com</a></p><p>Zentiva, k.s. : +30 211 198 <a href="mailto:7PV-Greece@zentiva.com">7PV-Greece@zentiva.com</a></p><p>sterreich Zentiva, k.s. Tel: +43 720 778 <a href="mailto:PV-Austria@zentiva.com">PV-Austria@zentiva.com</a> Espa a Zentiva, k.s. Tel: +34 931 815 <a href="mailto:PV-Spain@zentiva.com">PV-Spain@zentiva.com</a></p><p>Polska Zentiva Polska Sp. z o.o. Tel: + 48 22 375 92 <a href="mailto:PV-Poland@zentiva.com">PV-Poland@zentiva.com</a> France Zentiva France T l: +33 (0) 800 089 <a href="mailto:PV-France@zentiva.com">PV-France@zentiva.com</a></p><p>Portugal Zentiva Portugal, Lda Tel: <a href="mailto:+351210601PV-Portugal@zentiva.com">+351210601PV-Portugal@zentiva.com</a> Hrvatska Zentiva d.o.o. Tel: +385 1 6641 <a href="mailto:PV-Croatia@zentiva.com">PV-Croatia@zentiva.com</a></p><p>Ireland Zentiva, k.s. Tel: +353 766 803 <a href="mailto:PV-Ireland@zentiva.com">PV-Ireland@zentiva.com</a></p><p>Rom nia ZENTIVA S.A. Tel: +4 021 304 <a href="mailto:7PV-Romania@zentiva.com">7PV-Romania@zentiva.com</a></p><p>Slovenija Zentiva, k.s. Tel: +386 360 00 <a href="mailto:PV-Slovenia@zentiva.com">PV-Slovenia@zentiva.com</a> sland Zentiva Denmark ApS S mi: +354 539 <a href="mailto:0PV-Iceland@zentiva.com">0PV-Iceland@zentiva.com</a></p><p>Slovensk republika Zentiva, a.s. Tel: +421 2 3918 <a href="mailto:3PV-Slovakia@zentiva.com">3PV-Slovakia@zentiva.com</a> Italia Zentiva Italia S.r.l. Tel: <a href="mailto:+39-02-38598PV-Italy@zentiva.com">+39-02-38598PV-Italy@zentiva.com</a> Suomi/Finland Zentiva Denmark ApS Puh/Tel: +358 942 598 <a href="mailto:PV-Finland@zentiva.com">PV-Finland@zentiva.com</a></p><p>Zentiva, k.s. : +357 240 30 <a href="mailto:PV-Cyprus@zentiva.com">PV-Cyprus@zentiva.com</a></p><p>Sverige Zentiva Denmark ApS Tel: +46 840 838 <a href="mailto:PV-Sweden@zentiva.com">PV-Sweden@zentiva.com</a> Latvija Zentiva, k.s. Tel: +371 <a href="mailto:67893PV-Latvia@zentiva.com">67893PV-Latvia@zentiva.com</a> United Kingdom (Northern Ireland) Zentiva, k.s. Tel: +44 (0) 800 090 <a href="mailto:2PV-United-Kingdom@zentiva.com">2PV-United-Kingdom@zentiva.com</a></p><p>This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp0c9e6c673a48a176c2c1114fdf6885b8"/>
<resource>
<MedicinalProductDefinition>
<id value="mp0c9e6c673a48a176c2c1114fdf6885b8"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp0c9e6c673a48a176c2c1114fdf6885b8"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp0c9e6c673a48a176c2c1114fdf6885b8</b></p><a name="mp0c9e6c673a48a176c2c1114fdf6885b8"> </a><a name="hcmp0c9e6c673a48a176c2c1114fdf6885b8"> </a><a name="mp0c9e6c673a48a176c2c1114fdf6885b8-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/06/376/001-005</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Irbesartan Zentiva 75 mg tablets.</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/06/376/001-005"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Irbesartan Zentiva 75 mg tablets."/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
